Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1657

1.

Evolving role of regorafenib for the treatment of advanced cancers.

Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J.

Cancer Treat Rev. 2020 Feb 20;86:101993. doi: 10.1016/j.ctrv.2020.101993. [Epub ahead of print] Review.

2.

Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer.

Sasaki A, Nakamura Y, Togashi Y, Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K.

Gastric Cancer. 2020 Mar 16. doi: 10.1007/s10120-020-01058-4. [Epub ahead of print]

PMID:
32180056
3.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group.

Eur J Cancer. 2020 Mar 12;130:63-71. doi: 10.1016/j.ejca.2020.02.009. [Epub ahead of print]

PMID:
32172199
4.

Re: "JACM Special Focus Issue on Challenges in Inter-Rater Reliability in Traditional Chinese Medicine": A Japanese Perspective.

Yoshino T, Watanabe K.

J Altern Complement Med. 2020 Mar 11. doi: 10.1089/acm.2019.0464. [Epub ahead of print] No abstract available.

PMID:
32167777
5.

The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer.

Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Ishii G, Kuwata T, Shitara K.

Clin Cancer Res. 2020 Mar 10. pii: clincanres.0075.2020. doi: 10.1158/1078-0432.CCR-20-0075. [Epub ahead of print]

PMID:
32156744
6.

Discrimination of prediction models between cold-heat and deficiency-excess patterns.

Maeda-Minami A, Yoshino T, Katayama K, Horiba Y, Hikiami H, Shimada Y, Namiki T, Tahara E, Minamizawa K, Muramatsu S, Yamaguchi R, Imoto S, Miyano S, Mima H, Mimura M, Nakamura T, Watanabe K.

Complement Ther Med. 2020 Mar;49:102353. doi: 10.1016/j.ctim.2020.102353. Epub 2020 Feb 20.

PMID:
32147085
7.

Technique, cell assembly, and measurement of T-dependent electrical resistivity of liquid Fe devoid of contamination at P, T conditions.

Ezenwa IC, Yoshino T.

Rev Sci Instrum. 2020 Feb 1;91(2):023903. doi: 10.1063/1.5112045.

PMID:
32113395
8.

KLF4 is required for suppression of histamine synthesis by polyamines during bone marrow-derived mast cell differentiation.

Nishimura K, Okamoto M, Shibue R, Mizuta T, Shibayama T, Yoshino T, Murakami T, Yamaguchi M, Tanaka S, Toida T, Igarashi K.

PLoS One. 2020 Feb 26;15(2):e0229744. doi: 10.1371/journal.pone.0229744. eCollection 2020.

9.

Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.

Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, Yamanaka T, Yoshino T.

Br J Cancer. 2020 Feb 25. doi: 10.1038/s41416-020-0766-1. [Epub ahead of print]

PMID:
32099097
10.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q.

Ann Oncol. 2020 Apr;31(4):480-486. doi: 10.1016/j.annonc.2019.12.007. Epub 2020 Jan 16.

PMID:
32085892
11.

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, García Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J.

Ann Oncol. 2019 Jul;30 Suppl 4:iv154. doi: 10.1093/annonc/mdz183.004. Epub 2019 Dec 4. No abstract available.

12.

SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer.

Watanabe J, Sato T, Kagawa Y, Oki E, Kuboki Y, Ikeda M, Ueno H, Kato T, Kusumoto T, Masuishi T, Yamaguchi K, Kanazawa A, Nishina T, Uetake H, Yamanaka T, Yoshino T.

Ann Oncol. 2019 Jul;30 Suppl 4:iv132. doi: 10.1093/annonc/mdz154.016. Epub 2019 Dec 4. No abstract available.

13.

VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.

Yoshino T, Bando H, Tsukada Y, Inamori K, Yuki S, Komatsu Y, Homma S, Uemura M, Kato T, Kotani D, Fukuoka S, Sasaki T, Nishizawa Y, Nakamura N, Wakabayashi M, Kojima M, Togashi Y, Sato A, Nishikawa H, Ito M.

Ann Oncol. 2019 Jul;30 Suppl 4:iv129. doi: 10.1093/annonc/mdz154.009. Epub 2019 Dec 4. No abstract available.

14.

RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC).

Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y, Kuramochi H, Ohori H, Nakamura M, Takahashi K, Maeda F, Komeno C, Takeuchi M, Fujii M, Yoshino T, Ichikawa W, Tsuji A.

Ann Oncol. 2019 Jul;30 Suppl 4:iv114. doi: 10.1093/annonc/mdz156.012. Epub 2019 Dec 4. No abstract available.

15.

ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Grothey A, Yaeger R, Paez D, Tabernero J, Taïeb J, Yoshino T, Groc M, Vedovato J, Chetaille E, Van Cutsem E.

Ann Oncol. 2019 Jul;30 Suppl 4:iv109. doi: 10.1093/annonc/mdz155.399. Epub 2019 Dec 4. No abstract available.

16.

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.

Muro K, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Ota M, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Yamanaka K, Mori I, Soeda J, Hihara M, Yamanaka T, Akagi K, Ochiai A, Yoshino T.

Ann Oncol. 2019 Jul;30 Suppl 4:iv10. doi: 10.1093/annonc/mdz155.033. Epub 2019 Dec 4. No abstract available.

17.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, Yoshino T, Douillard JY.

Ann Oncol. 2020 Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Epub 2020 Jan 16.

PMID:
32081575
18.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY.

Ann Oncol. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. Epub 2019 Dec 20.

PMID:
32067677
19.

BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.

Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB.

Clin Cancer Res. 2020 Feb 11. pii: clincanres.3579.2019. doi: 10.1158/1078-0432.CCR-19-3579. [Epub ahead of print]

20.

Hemosiderin deposition in lymph nodes of patients with plasma cell-type Castleman disease.

Han Y, Igawa T, Ogino K, Nishikori A, Gion Y, Yoshino T, Sato Y.

J Clin Exp Hematop. 2020 Feb 8. doi: 10.3960/jslrt.19037. [Epub ahead of print]

21.

[CD20-negative diffuse large B-cell lymphoma complicated by rheumatoid arthritis].

Yoshino T, Makiyama J, Imaizumi Y, Matsuo E, Kitanosono H, Nakashima J, Kato T, Miyoshi H, Ohshima K, Yoshida S, Miyazaki Y.

Rinsho Ketsueki. 2020;61(1):33-38. doi: 10.11406/rinketsu.61.33. Japanese.

PMID:
32023600
22.

A comparative study of sulphated polysaccharide effects on advanced glycation end-product uptake and scavenger receptor class A level in macrophages.

Nishinaka T, Mori S, Yamazaki Y, Niwa A, Wake H, Yoshino T, Nishibori M, Takahashi H.

Diab Vasc Dis Res. 2020 Jan-Feb;17(1):1479164119896975. doi: 10.1177/1479164119896975.

PMID:
32000529
23.

Diverse Approaches for Enantioselective C-H Functionalization Reactions Using Group 9 CpxMIII Catalysts.

Yoshino T, Satake S, Matsunaga S.

Chemistry. 2020 Jan 28. doi: 10.1002/chem.201905417. [Epub ahead of print]

PMID:
31994236
24.

Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.

Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H.

Int J Clin Oncol. 2020 Mar;25(3):403-417. doi: 10.1007/s10147-019-01610-y. Epub 2020 Jan 24.

25.

Selection and characterization of microalgae with potential for nutrient removal from municipal wastewater and simultaneous lipid production.

Aketo T, Hoshikawa Y, Nojima D, Yabu Y, Maeda Y, Yoshino T, Takano H, Tanaka T.

J Biosci Bioeng. 2020 Jan 20. pii: S1389-1723(19)30856-4. doi: 10.1016/j.jbiosc.2019.12.004. [Epub ahead of print]

PMID:
31974048
26.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn YC, Kim TY, Ahn HK, Peters S, Yoshino T, Douillard JY.

Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.

PMID:
31959336
27.

Characterization of a novel marine unicellular alga, Pseudoneochloris sp. strain NKY372003 as a high carbohydrate producer.

Aketo T, Hashizume R, Yabu Y, Hoshikawa Y, Nojima D, Maeda Y, Yoshino T, Takano H, Tanaka T.

J Biosci Bioeng. 2020 Jan 11. pii: S1389-1723(19)30959-4. doi: 10.1016/j.jbiosc.2019.12.010. [Epub ahead of print]

PMID:
31937470
28.

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.

Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ.

Ann Oncol. 2020 Jan;31(1):88-95. doi: 10.1016/j.annonc.2019.10.005.

29.

Clinicopathologic analysis of gastric mucosa-associated lymphoid tissue lymphoma with or without c-Met expression.

Omote R, Gion Y, Omote S, Tari A, Tanaka T, Nishikori A, Yoshino T, Sato Y.

Med Mol Morphol. 2020 Jan 2. doi: 10.1007/s00795-019-00241-6. [Epub ahead of print]

PMID:
31897734
30.

MACC1 expression is an indicator of recurrence in early-stage glottic cancer.

Makino T, Orita Y, Gion Y, Tachibana T, Takao S, Marunaka H, Miki K, Akisada N, Akagi Y, Yoshino T, Nishizaki K, Sato Y.

Jpn J Clin Oncol. 2020 Jan 2. pii: hyz206. doi: 10.1093/jjco/hyz206. [Epub ahead of print]

PMID:
31894242
31.

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.

Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, Bando H, Taniguchi H, Shitara K, Kojima T, Tsuji A, Yoshino T.

BMC Cancer. 2019 Dec 27;19(1):1253. doi: 10.1186/s12885-019-6475-6.

32.

Gene drives for schistosomiasis transmission control.

Maier T, Wheeler NJ, Namigai EKO, Tycko J, Grewelle RE, Woldeamanuel Y, Klohe K, Perez-Saez J, Sokolow SH, De Leo GA, Yoshino TP, Zamanian M, Reinhard-Rupp J.

PLoS Negl Trop Dis. 2019 Dec 19;13(12):e0007833. doi: 10.1371/journal.pntd.0007833. eCollection 2019 Dec. Review.

33.

SARC-F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease.

Hiraoka A, Nagamatsu K, Izumoto H, Yoshino T, Adachi T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K.

Hepatol Res. 2019 Dec 12. doi: 10.1111/hepr.13469. [Epub ahead of print]

PMID:
31830344
34.

Japanese government research grants for Kampo medicine: aAn overview of 10 years (1997-2017).

Hyun MK, Yoon HY, Yoshino T, Park MJ.

Integr Med Res. 2019 Dec;8(4):279-283. doi: 10.1016/j.imr.2019.11.006. Epub 2019 Nov 14.

35.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T.

ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

36.

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kitano S, Kojima T, Daiko H, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A.

Br J Cancer. 2020 Feb;122(3):413-420. doi: 10.1038/s41416-019-0622-3. Epub 2019 Nov 25.

PMID:
31761900
37.

Longitudinal Analysis of Bidirectional Relationships between Nocturia and Depressive Symptoms: The Nagahama Study.

Funada S, Tabara Y, Negoro H, Akamatsu S, Yoshino T, Yoshimura K, Watanabe N, Furukawa T, Matsuda F, Ogawa O.

J Urol. 2019 Nov 21:101097JU0000000000000683. doi: 10.1097/JU.0000000000000683. [Epub ahead of print]

PMID:
31750764
38.

Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus.

Hiraoka A, Nagamatsu K, Izumoto H, Adachi T, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Suga Y, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K.

Hepatol Res. 2020 Jan;50(1):92-100. doi: 10.1111/hepr.13430. Epub 2019 Nov 24.

PMID:
31729124
39.

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T.

J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14.

PMID:
31725351
40.

LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.

Inoue T, Kaneko T, Muramatsu S, Kimura H, Yoshino T, Goto T, Sawada A, Akamatsu S, Kobayashi T, Yamasaki T, Kaya T, Ogawa O.

Clin Genitourin Cancer. 2020 Feb;18(1):e28-e36. doi: 10.1016/j.clgc.2019.10.011. Epub 2019 Oct 17.

PMID:
31711843
41.

[Clinical Effect of Nivolumab on Advanced Renal Cell Carcinoma with Peritoneal Metastasis].

Hida T, Yamasaki T, Banno H, Fuchigami Y, Hattahara K, Fujiwara M, Suzuki R, Kita Y, Yoshino T, Goto T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O.

Hinyokika Kiyo. 2019 Oct;65(10):413-419. doi: 10.14989/ActaUrolJap_65_10_413. Japanese.

PMID:
31697887
42.

Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.

Demachi K, Bando H, Nomura H, Shitara K, Yoshino T, Yamaguchi M, Kawasaki T.

Jpn J Clin Oncol. 2020 Feb 17;50(2):129-137. doi: 10.1093/jjco/hyz157.

PMID:
31693138
43.

Hepatic transcriptional profile and tissue distribution of cytochrome P450 1-3 genes in the red-crowned crane Grus japonensis.

Kawai YK, Itou K, Yoshino T, Iima H, Matsumoto F, Kubota A.

Comp Biochem Physiol C Toxicol Pharmacol. 2020 Feb;228:108643. doi: 10.1016/j.cbpc.2019.108643. Epub 2019 Nov 13.

PMID:
31669699
44.

Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review.

Makimoto G, Ohashi K, Taniguchi K, Soh J, Taniguchi A, Miyahara N, Toyooka S, Yoshino T, Maeda Y, Kiura K.

Respir Med Case Rep. 2019 Sep 24;28:100938. doi: 10.1016/j.rmcr.2019.100938. eCollection 2019.

45.

Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study.

Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, Yoshino T.

Jpn J Clin Oncol. 2020 Feb 17;50(2):122-128. doi: 10.1093/jjco/hyz149.

PMID:
31665356
46.

Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).

Kageyama C, Igawa T, Gion Y, Iwaki N, Tabata T, Tanaka T, Kondo E, Sakai H, Tsuneyama K, Nomoto K, Noguchi H, Yoshino T, Yokota K, Sato Y.

Pathol Int. 2019 Oct;69(10):572-579. doi: 10.1111/pin.12856.

PMID:
31631463
47.

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.

Lenz HJ, Argiles G, Yoshino T, Lonardi S, Falcone A, Limón ML, Sobrero A, Hastedt C, Peil B, Voss F, Griebsch I, Van Cutsem E.

Clin Colorectal Cancer. 2019 Dec;18(4):269-279.e5. doi: 10.1016/j.clcc.2019.08.005. Epub 2019 Sep 4.

48.

Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study.

Takahashi K, Yoshino T, Maki Y, Ishiuchi K, Namiki T, Ogawa-Ochiai K, Minamizawa K, Makino T, Nakamura T, Mimura M, Watanabe K.

Arch Toxicol. 2019 Nov;93(11):3111-3119. doi: 10.1007/s00204-019-02588-2. Epub 2019 Oct 11.

PMID:
31605160
49.

Catalytic Enantioselective Methylene C(sp3 )-H Amidation of 8-Alkylquinolines Using a Cp*RhIII /Chiral Carboxylic Acid System.

Fukagawa S, Kojima M, Yoshino T, Matsunaga S.

Angew Chem Int Ed Engl. 2019 Dec 9;58(50):18154-18158. doi: 10.1002/anie.201911268. Epub 2019 Nov 11.

PMID:
31593365
50.

Rapid discrimination of fungal species by the colony fingerprinting.

Maeda Y, Sugiyama Y, Lim TK, Harada M, Yoshino T, Matsunaga T, Tanaka T.

Biosens Bioelectron. 2019 Dec 15;146:111747. doi: 10.1016/j.bios.2019.111747. Epub 2019 Sep 30.

PMID:
31586763

Supplemental Content

Loading ...
Support Center